ストックスクリーナーアプリを入手
5.39
3.26%
0.17
アフターアワーズ：
5.39
前日終値:
$5.22
開ける：
$5.31
24時間の取引高:
24.18M
Relative Volume:
0.93
時価総額：
$2.15B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-3.4774
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
-3.58%
1か月 パフォーマンス:
+7.80%
6か月 パフォーマンス:
-15.78%
1年 パフォーマンス:
-37.33%
1日の値動き範囲:
$5.205
$5.555
1週間の範囲:
$5.13
$5.8793
52週間の値動き範囲:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.39 | 2.32B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - The Globe and Mail
With 68% institutional ownership, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a favorite amongst the big guns - simplywall.st
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch. - The Motley Fool
(RXRX) Technical Data - news.stocktradersdaily.com
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing - sharewise.com
Recursion Pharma Surges: An Unexpected 12% Jump - StocksToTrade
Recursion Pharmaceuticals: Leveraging AI and Strategic Partnerships to Tackle Rare Diseases - AInvest
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - Yahoo Finance
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey
RXRX: Market Moves and Future Projections - timothysykes.com
Recursion Pharmaceuticals: The AI Drug Discovery Play - Nasdaq
These 10 Stocks Are Making Big Moves - Insider Monkey
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking - Insider Monkey
Here's Why Shares in Recursion Pharmaceuticals Surged Today - Yahoo Finance
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion Pharmaceuticals Teams Up with MIT to Boost Drug Discovery - StocksToTrade
Recursion Pharmaceuticals Expands Strategic Reach with MIT Partnership - timothysykes.com
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Recursion Pharmaceuticals Acquires Full Interest in Joint Hypophosphatasia Candidate From Rallybio - MarketScreener
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Business Wire
What's Happening With RXRX Stock? - Forbes
Recursion Pharmaceuticals Faces Financial Headwinds Amid Strategic Changes - timothysykes.com
Recursion Pharmaceuticals Stock Adjustments: What’s Next? - StocksToTrade
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? - The Globe and Mail
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today - Nasdaq
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? - The Globe and Mail
MIT & Recursion Unveil Boltz-2, Accelerates Drug Discovery 1000x, Rivals Physics-Based Accuracy - Insider Monkey
Why This Wildcard Stock Could Be A Future Star - Barchart.com
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Morgan Stanley Trims Recursion (RXRX) Price Target, Maintains Equal Weight Rating - Insider Monkey
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Transcript : Recursion Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - MarketScreener
Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI - MSN
Recursion Pharmaceuticals stockholders elect three Class I directors - Investing.com Australia
Recursion Pharmaceuticals stockholders elect three Class I directors By Investing.com - Investing.com India
Recursion Pharmaceuticals Holds Annual Stockholder Meeting - TipRanks
Recursion Pharmaceuticals: Surging or Sinking? - timothysykes.com
Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
Recursion Pharmaceuticals (RXRX): Morgan Stanley Adjusts Price Target | RXRX Stock News - GuruFocus
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Recursion Pharma to reduce workforce by 20% - MSN
Why Recursion Pharmaceuticals Stock Is Plummeting Today - AOL.com
Recursion Pharmaceuticals price target lowered to $5 by Morgan Stanley - Investing.com Canada
Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley - TipRanks
Morgan Stanley Cuts Recursion Pharmaceuticals Price Target to $5 From $8, Maintains Equalweight Rating - MarketScreener
Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? - MSN
Why Recursion Pharmaceuticals RXRX Could Be the NVDA of Biotech for NASDAQ:RXRX by TopgOptions - TradingView
Recursion to lay off 20% of workforce, narrows focus amid biotech downturn - MSN
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
3.40%
2.49%
大文字化:
|
ボリューム (24 時間):